Fragmentomics features of ovarian cancer
International Journal of Cancer · 2024-10 · 155 (7) · 1316-1326
DOI: 10.1002/ijc.34981 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 20.05.2024. Verfasst von Xiaopei Chao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Biomarkers, Tumor, Circulating Tumor DNA, Machine Learning. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS), China Postdoctoral Science Foundation, Key Research Project of Beijing Natural Science Foundation.
Abstract (Originalsprache)
Ovarian cancer (OC) is a major cause of cancer mortality in women worldwide. Due to the occult onset of OC, its nonspecific clinical symptoms in the early phase, and a lack of effective early diagnostic tools, most OC patients are diagnosed at an advanced stage. In this study, shallow whole‐genome sequencing was utilized to characterize fragmentomics features of circulating tumor DNA (ctDNA) in OC patients. By applying a machine learning model, multiclass fragmentomics data achieved a mean area under the curve (AUC) of 0.97 (95% CI 0.962–0.976) for diagnosing OC. OC scores derived from this model strongly correlated with the disease stage. Further comparative analysis of OC scores illustrated that the fragmentomics‐based technology provided additional clinical benefits over the traditional serum biomarkers cancer antigen 125 (CA125) and the Risk of Ovarian Malignancy Algorithm (ROMA) index. In conclusion, fragmentomics features in ctDNA are potential biomarkers for the accurate diagnosis of OC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China.
- Department of Gynecologic Oncology, National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China.
- State Key Laboratory for Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.
- Department of Bioinformatics, Zhejiang Shaoxing Topgen Biomedical Technology CO., LTD, Shanghai, China.
- Department of Pathology, Peking Union Medical College Hospital, Beijing, China.
- Department of Technology, Zhejiang Topgen Clinical Laboratory Co., LTD., Huzhou, China.
ORCID-Profile: Xiaopei Chao, Zhentian Kai, Huanwen Wu, Jing Wang, Xiaojing Chen, Haiqi Su, Xiao Shang, Ruijue Lin, Lisha Huang, Hongsheng He, Jinghe Lang, Lei Li
Förderung
- Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS)
- China Postdoctoral Science Foundation
- Key Research Project of Beijing Natural Science Foundation
- State Key Laboratory for Complex, Severe and Rare Diseases in Peking Union Medical College Hospital
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Chao, X., Kai, Z., Wu, H., Wang, J., Chen, X., Su, H., Shang, X., Lin, R., Huang, L., He, H., Lang, J., & Li, L. (2024). Fragmentomics features of ovarian cancer. International Journal of Cancer, 155(7), 1316-1326. https://doi.org/10.1002/ijc.34981
Vancouver
Chao X, Kai Z, Wu H, Wang J, Chen X, Su H, et al. Fragmentomics features of ovarian cancer. International Journal of Cancer. 2024;155(7):1316-1326. doi:10.1002/ijc.34981
BibTeX
@article{Chao2024,
author = {Chao, Xiaopei and Kai, Zhentian and Wu, Huanwen and Wang, Jing and Chen, Xiaojing and Su, Haiqi and Shang, Xiao and Lin, Ruijue and Huang, Lisha and He, Hongsheng and Lang, Jinghe and Li, Lei},
title = {Fragmentomics features of ovarian cancer},
journal = {International Journal of Cancer},
year = {2024},
volume = {155},
number = {7},
pages = {1316--1326},
doi = {10.1002/ijc.34981}
}
EUVIMED